Celator Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops therapies to treat cancer. Its proprietary drug ratio technology platform, CombiPlex, enables the rational design and rapid evaluation of optimized combinations incorporating traditional chemotherapies, as well as molecularly targeted agents to deliver enhanced anti-cancer activity. The company's product pipeline includes CPX-351, a liposomal formulation of cytarabine:daunorubicin, which is in Phase III study for the treatment of acute myeloid leukemia; and CPX-1, a liposomal formulation of irinotecan:floxuridine that has completed Phase II study for the treatment of colorectal cancer. Its preclinical stage product candidate is CPX-8, a hydrophobic docetaxel prodrug nanoparticle formulation for vitro and vivo studies. The company was founded in 1999 and is headquartered in Ewing, New Jersey.
CPXX took off last month on this news: Celator Announces Phase 3 Trial for VYXEOS (CPX-351) in Patients with High-Risk Acute Myeloid Leukemia Demonstrates Statistically Significant Improvement in Overall Survival PR Newswire "Press Releases US - English" EWING, N.J., March 14, 2016 /PRNewswire/ -- Celator Pharmaceuticals, Inc. (Nasdaq: CPXX) today announced positive results from the Phase 3 trial of VYXEOS (cytarabine: daunorubicin) Liposome for Injection (also known as CPX-351) in patients with high-risk (secondary) acute myeloid leukemia (AML) compared to the standard of care regimen of cytarabine and daunorubicin known as 7+3. The trial met its primary endpoint demonstrating a statistically significant improvement in overall survival. Data will be submitted for presentation at the American Society of Clinical Oncology 2016 Annual Meeting.
That is some serious whipsaw action! This make close strong, but it might also scare some longs into locking in some profits. The stock has been going straight up for over a month!
What an entrance that low would have been today if you could get out right now (or even continue to hold). Wish this would have been on my radar with a bid in for that area.
It's income statement also looks like a joke. Don't need much analyzing here. Fundamentals will drive this price down sooner or later
+71% Celator Pharmaceuticals Inc (NASDAQ:CPXX)’s stock skyrocketed more than 71% after the company announced that it is being acquired by Jazz Pharmaceuticals plc – Ordinary Shares (NASDAQ:JAZZ) for $30.25 per share in cash, or approximately $1.5 billion. Back in March, the Princeton, New Jersey-based pharmaceutical company surprised investors and analysts with positive results from a trial of its leukemia drug Vyxeos. The stock surged by more than 400% after the announcement of the results. In a statement, Bruce Cozadd, Jazz’s CEO, said that Vyxeos, for which Celator is set to apply for approval, will allow the company to add a major revenue stream in the future. Shares of Jazz Pharmaceuticals are flat in trading today.
http://www.marketwatch.com/story/ce...ficantly-improved-overall-survival-2016-06-06 EWING, N.J., June 6, 2016 /PRNewswire/ -- Celator Pharmaceuticals, Inc. CPXX, -0.73% today announced results from its Phase 3 trial of VYXEOS™ (cytarabine:daunorubicin) Liposome for Injection (also known as CPX-351) in patients with high-risk (secondary) acute myeloid leukemia (AML) were presented at the American Society of Clinical Oncology (ASCO) 2016 Annual Meeting. As previously reported, the trial met its primary endpoint demonstrating a statistically significant improvement in overall survival. The Phase 3 trial compared to the standard of care regimen of cytarabine and daunorubicin known as 7+3. Looks promising. ;p
